Chinese medical journal · 1998
In vivo hydrogen-1 magnetic resonance spectroscopy study of human intracranial tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luan W, Zhang J
Аннотация
OBJECTIVE: To investigate the metabolic changes, pathological state and histological types of intracranial tumors with hydrogen-1 magnetic resonance spectroscopy (H-1 MRS).
METHODS: Thirteen patients with intracranial tumors were studied with localized proton magnetic resonance spectroscopy (H-1MRS), in vivo. All spectra were obtained with a 2.0 T whole body MR imaging system.
RESULTS: All the spectra of these tumors exhibited high ratios of choline (Cho)/creatine (Cr) and Cho/N-acetyl aspartate (NAA), and histologically different tumors showed obvious variations in the metabolite ratios. Significant differences of Cho/Cr ratio were found between meningiomas and astrocytomas by statistical evaluation. The spectra obtained after operation were remarkably different from those before operation.
CONCLUSION: H-1 MRS can serve as a non-invasive clinical test for therapeutic and prognostic uses for intracranial tumors.
METHODS: Thirteen patients with intracranial tumors were studied with localized proton magnetic resonance spectroscopy (H-1MRS), in vivo. All spectra were obtained with a 2.0 T whole body MR imaging system.
RESULTS: All the spectra of these tumors exhibited high ratios of choline (Cho)/creatine (Cr) and Cho/N-acetyl aspartate (NAA), and histologically different tumors showed obvious variations in the metabolite ratios. Significant differences of Cho/Cr ratio were found between meningiomas and astrocytomas by statistical evaluation. The spectra obtained after operation were remarkably different from those before operation.
CONCLUSION: H-1 MRS can serve as a non-invasive clinical test for therapeutic and prognostic uses for intracranial tumors.